Gustafsson D - Search Results

1

Discovery of ximelagatran in an historical perspective.

Gustafsson D. Gustafsson D. Semin Vasc Med. 2005 Aug;5(3):227-34. doi: 10.1055/s-2005-916161. Semin Vasc Med. 2005. PMID: 16123909 Review.

2

Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.

Eriksson UG, Bredberg U, Hoffmann KJ, Thuresson A, Gabrielsson M, Ericsson H, Ahnoff M, Gislén K, Fager G, Gustafsson D. Eriksson UG, et al. Among authors: gustafsson d. Drug Metab Dispos. 2003 Mar;31(3):294-305. doi: 10.1124/dmd.31.3.294. Drug Metab Dispos. 2003. PMID: 12584156

3

The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.

Gustafsson D, Elg M. Gustafsson D, et al. Thromb Res. 2003 Jul 15;109 Suppl 1:S9-15. doi: 10.1016/s0049-3848(03)00249-4. Thromb Res. 2003. PMID: 12818629 Review.

4

Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.

Sarich TC, Eriksson UG, Mattsson C, Wolzt M, Frison L, Fager G, Gustafsson D. Sarich TC, et al. Among authors: gustafsson d. Thromb Haemost. 2002 Feb;87(2):300-5. Thromb Haemost. 2002. PMID: 11858491 Clinical Trial.

5

Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.

Eriksson UG, Bredberg U, Gislén K, Johansson LC, Frison L, Ahnoff M, Gustafsson D. Eriksson UG, et al. Among authors: gustafsson d. Eur J Clin Pharmacol. 2003 May;59(1):35-43. doi: 10.1007/s00228-003-0565-7. Epub 2003 Mar 27. Eur J Clin Pharmacol. 2003. PMID: 12743672 Clinical Trial.

6

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Johansson LC, et al. Among authors: gustafsson d. Clin Pharmacokinet. 2003;42(4):381-92. doi: 10.2165/00003088-200342040-00006. Clin Pharmacokinet. 2003. PMID: 12648028 Clinical Trial.

7

No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.

Johansson LC, Andersson M, Fager G, Gustafsson D, Eriksson UG. Johansson LC, et al. Among authors: gustafsson d. Clin Pharmacokinet. 2003;42(5):475-84. doi: 10.2165/00003088-200342050-00005. Clin Pharmacokinet. 2003. PMID: 12739985 Clinical Trial.

8

Oral direct thrombin inhibitors in clinical development.

Gustafsson D. Gustafsson D. J Intern Med. 2003 Oct;254(4):322-34. doi: 10.1046/j.1365-2796.2003.01225.x. J Intern Med. 2003. PMID: 12974871 Free article. Review.

9

Acute antithrombotic effects of ximelagatran, an oral direct thrombin inhibitor, and r-hirudin in a human ex vivo model of arterial thrombosis.

Sarich TC, Osende JI, Eriksson UG, Fager GB, Eriksson-Lepkowska M, Ohlsson L, Carlsson S, Wåhlander K, Gustafsson D, Badimon JJ. Sarich TC, et al. Among authors: gustafsson d. J Thromb Haemost. 2003 May;1(5):999-1004. doi: 10.1046/j.1538-7836.2003.00201.x. J Thromb Haemost. 2003. PMID: 12871368 Free article. Clinical Trial.

10

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.

Eriksson UG, Mandema JW, Karlsson MO, Frison L, Gisleskog PO, Wählby U, Hamrén B, Gustafsson D, Eriksson BI. Eriksson UG, et al. Among authors: gustafsson d. Clin Pharmacokinet. 2003;42(7):687-701. doi: 10.2165/00003088-200342070-00006. Clin Pharmacokinet. 2003. PMID: 12844328 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

162 results

Search Page